<DOC>
	<DOCNO>NCT00004235</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness combine docetaxel irinotecan treating patient advance cancer esophagus stomach .</brief_summary>
	<brief_title>Docetaxel Irinotecan Treating Patients With Advanced Cancer Esophagus Stomach</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective tumor response rate patient advance adenocarcinoma low esophagus , esophagogastric junction , gastric cardia treat docetaxel irinotecan . II . Determine time progression overall survival patient treat treated regimen . III . Determine toxic effect regimen patient . IV . Assess treatment response patient determine prevalence dysphagia , anorexia , swallow ability diagnosis treatment regimen .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma low esophagus , esophagogastric junction , gastric cardia consider unresectable curative therapy exist No conventional form therapy available would offer reasonable chance cure significant palliation Gastric cardia define great 5 cm esophagogastric junction stomach Measurable disease At least 1 lesion accurately measure least 1 dimension least 20 mm No nonmeasurable lesion , include : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No known untreated treated symptomatic CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST great ULN ( less 2.5 time ULN alkaline phosphatase great ULN ) Alkaline phosphatase great ULN ( 4 time ULN AST great ULN ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Neurologic : No grade 2 great peripheral neuropathy etiology No uncontrolled seizure disorder Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Ability complete questionnaire alone assistance No uncontrolled infection No chronic debilitate disease No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer noninvasive carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy biologic therapy recurrent metastatic disease No concurrent biologic therapy No concurrent filgrastim ( GCSF ) primary prophylaxis Chemotherapy : Prior adjuvant chemotherapy complete resection original tumor allow Prior neoadjuvant chemotherapy allow No prior chemotherapy recurrent metastatic disease No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior adjuvant radiotherapy complete resection original tumor allow Prior neoadjuvant radiotherapy allow At least 4 week since prior radiotherapy No prior radiotherapy recurrent metastatic disease No prior radiotherapy 25 % bone marrow No concurrent radiotherapy except CNS Surgery : See Disease Characteristics Prior surgical resection primary tumor allow At least 4 week since prior abdominal exploration resection ( 3 week without resection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>